Kings Path Partners
MRK icon

Kings Path Partners’s Merck MRK Stock Holding History

Kings Path Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$408K Buy
2,809
+201
+8% +$27.8K 0.11% 75
2026
Q2 		$335K Buy
2,608
+8
+0.3% +$936 0.09% 90
2026
Q1 		$313K Hold
2,600
– – 0.11% 90
2025
Q4 		$274K Hold
2,600
– – 0.1% 91
2025
Q3 		$218K Hold
2,600
– – 0.08% 98
2025
Q2 		$206K Hold
2,600
– – 0.08% 95
2025
Q1 		$233K Hold
2,600
– – 0.11% 92
2024
Q4 		$259K Sell
2,600
-25
-1% -$2.58K 0.11% 116
2024
Q3 		$298K Hold
2,625
– – 0.13% 111
2024
Q2 		$325K Buy
+2,625
New +$338K 0.15% 104

Other funds holding MRK

Smead Capital Management
Smead Capital Management Phoenix, Arizona $4.71B AUM 32.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Quilter Plc
Quilter Plc London, United Kingdom $6.95B AUM 39.67% 1-Year Est. Return
Cardano Risk Management
Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return
UniSuper Management
UniSuper Management Melbourne, Victoria, Australia $20.4B AUM 33.79% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Kings Path Partners's MRK Position: Q3 2026 in Review

Kings Path Partners increased its Merck (MRK) stake by 7.7% in Q3 2026, buying an estimated $27.8K and bringing the position to 2,809 shares worth $408K. The position accounts for 0.11% of the portfolio, ranked #75.

Kings Path Partners first reported a position in MRK in Q2 2024 and has held it in 10 quarters since. 1,390 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Kings Path Partners held 2,809 shares of Merck worth $408K as of Q3 2026.
  • Kings Path Partners bought 201 Merck shares in Q3 2026, an estimated $27.8K.
  • Merck made up 0.11% of Kings Path Partners's portfolio in Q3 2026, its #75 holding.
  • Kings Path Partners first reported a position in Merck in Q2 2024 and has held it in 10 quarters since.
  • 1,390 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Kings Path Partners's 13F filing for Q3 2026, filed 21 Oct 2026.